Elona Biotech selling biosimilar insulin patents for $2.2 million

September 4, 2013 9:08 AM

A court-appointed receiver for Elona Biotechnologies announced it was selling the company’s complete portfolio of patents, intellectual property and equipment for a “buy it now” price of $2.2 million. If an offer of $2.2 million is not received by September 6, the receiver said the company’s patents and real estate will be sold by auction on September 27.

The Indiana-based company made an ambitious announcement in 2010 that it was developing its own biosimilar insulin plant. The firm subsequently built a 50,000 square foot manufacturing plant outside of Indianapolis, but was forced into receivership just as the building was being completed.

Elona was founded by two Eli Lilly executives, and was seen as a major player in the biosimilar insulin space, along with the Sandoz unit of Novartis, India-based Biocon and Israel-based Teva Pharmaceuticals. Meanwhile, Elona’s neighbor Lilly continues to be a global leader in insulin sales, with revenues exceeding $1.3 billion for its Humulin brand and $2.4 billion for Humalog. However, Humulin’s patent expired in 2000 and Humalog is set to expire this year.

With the FDA’s release last year of draft guidelines for the approval of biosimilars, many believe biosimilar insulin will eventually mount a challenge to current dominant companies in the insulin market.

 

Source: Key Auctioneers press release

 

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!